Champions Oncology
Champions Oncology, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America and Europe. Founded in 2010, the company has made significant strides in advancing personalised cancer treatment through its innovative technology platforms. Specialising in the development of patient-derived xenograft (PDX) models, Champions Oncology offers unique solutions that enable oncologists to tailor therapies based on individual tumour characteristics. This approach not only enhances treatment efficacy but also optimises patient outcomes. With a strong market position, Champions Oncology has garnered recognition for its contributions to cancer research and personalised medicine, solidifying its reputation as a trusted partner in the fight against cancer.
DitchCarbon Score
How does Champions Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Champions Oncology's score of 26 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Champions Oncology's reported carbon emissions
Champions Oncology, headquartered in CN, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. The company has committed to a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This target aligns with the science-based targets necessary to limit global warming to 1.5°C, reflecting a strong commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. While specific emissions data for the most recent year is not available, Champions Oncology's proactive approach includes plans to measure and reduce its Scope 3 emissions as well. This comprehensive strategy underscores the company's dedication to addressing its overall carbon footprint and contributing to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Champions Oncology is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
